Minerva Neurosciences (NERV) Operating Leases (2019 - 2020)
Minerva Neurosciences posted quarterly Operating Leases of $16288.0 for Q2 2020, down 91.9% year-on-year from $201066.0 in Q3 2019, and down 74.69% on a QoQ basis from $64350.0 in Q1 2020.
Minerva Neurosciences (NERV) has 2 years of Operating Leases data on file, last reported at $16288.0 in Q2 2020.
- For the quarter ending Q2 2020, Operating Leases fell 91.9% year-over-year to $16288.0; the trailing twelve-month figure through Jun 2020 stood at $16288.0 (down 91.9% YoY), and the FY2019 full-year result was $111229.0, changed N/A from the prior year.
- Operating Leases for Q2 2020 stood at $16288.0, down from $64350.0 in the prior quarter.
- Across five years, Operating Leases topped out at $243115.0 in Q1 2019 and bottomed at $16288.0 in Q2 2020.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Minerva Neurosciences | 215.11 Mn | 215.11 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2020 | 16,288.00 |
| Mar 31, 2020 | 64,350.00 |
| Dec 31, 2019 | 111,229.00 |
| Sep 30, 2019 | 156,956.00 |
| Jun 30, 2019 | 201,066.00 |
| Mar 31, 2019 | 243,115.00 |